Structural and ligand-binding properties of serum albumin species interacting with a biomembrane interface.

Structural and ligand-binding properties of serum albumin species interacting with a biomembrane interface. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Structural and ligand-binding properties of serum albumin species interacting with a biomembrane interface. Abstract Text:

Takamitsu Kosa,Koji Nishi,Toru Maruyama,Norifumi Sakai,Naoko Yonemura,Hiroshi Watanabe,Ayaka Suenaga,Masaki Otagiri,Takamitsu Kosa,Koji Nishi,Toru Maruyama,Norifumi Sakai,Naoko Yonemura,Hiroshi Watanabe,Ayaka Suenaga,Masaki Otagiri,

In the process of drug development, preclinical testing using experimental animals is an important aspect, for verification of the efficacy and safety of a drug. Serum albumin is a major binding protein for endogenous and exogenous ligands and regulates their distribution in various tissues. In this study, the structural and drug-binding properties of albumins on a biomembrane surface were investigated using reverse micelles as a model membrane. In reverse micelles, the secondary structures of all albumins were found, to varying degrees, to be intermediate between the native and denatured states. The tertiary structures of human and bovine albumin were similar to those of the native and intermediate states, respectively, whereas those of the dog, rabbit, and rat were in a denatured state. Thus, bovine albumin is an appropriate model for studying structural changes in human albumin in a membrane-water phase. Binding studies also showed the presence of species difference in the change in binding capacity of albumins during their interaction with reverse micelles. Among the albumins, rat albumin appears to be a good model for the protein-mediated drug uptake of human albumin in a biomembrane environment. These findings are significant in terms of the appropriate extrapolation of pharmacokinetics and pharmacodynamics data in various animals to humans.

Structural and ligand-binding properties of serum albumin species interacting with a biomembrane interface. Publishing Authors By Initials

T Kosa,K Nishi,T Maruyama,N Sakai,N Yonemura,H Watanabe,A Suenaga,M Otagiri,T Kosa,K Nishi,T Maruyama,N Sakai,N Yonemura,H Watanabe,A Suenaga,M Otagiri,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Structural and ligand-binding properties of serum albumin species interacting with a biomembrane interface. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of pharmaceutical sciences

VOLUME: 96

Page Numbers: 3117-24

Journal Abbreviation:

ISSN: 0022-3549

DAY: 5

MONTH: Nov

YEAR: 2007

Structural and ligand-binding properties of serum albumin species interacting with a biomembrane interface. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2985195

Structural and ligand-binding properties of serum albumin species interacting with a biomembrane interface. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Structural and ligand-binding properties of serum albumin species interacting with a biomembrane interface. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Structural and ligand-binding properties of serum albumin species interacting with a biomembrane interface.

AFFILIATION: Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862-0973, Japan.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Pharm Sci

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Structural and ligand-binding properties of serum albumin species interacting with a biomembrane interface Related Publications

• CD36 is not involved in scavenger receptor-mediated endocytic uptake of glycolaldehyde- and methylglyoxal-modified proteins by liver endothelial cells.
• Changes of net charge and alpha-helical content affect the pharmacokinetic properties of human serum albumin.
• Comparison of Pharmacokinetics between Highly and Mildly Modified AGE Proteins in Mice.
• Design and evaluation of S-nitrosylated human serum albumin as a novel anticancer drug.
• Effects of endogenous ligands on the biological role of human serum albumin in S-nitrosylation.
• Effects of high-frequency oscillatory ventilation on oleic Acid-induced lung injury in sheep.
• Identification of Human Liver Cytochrome P450 Isoforms Involved in Autoinduced Metabolism of the Antiangiogenic Agent (Z)-5-[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic Acid (TSU-68).
• Recombinant human serum albumin.
• Structural and ligand-binding properties of serum albumin species interacting with a biomembrane interface.
• Subdomain IIIA of Dog Albumin Contains a Binding Site Similar to Site II of Human Albumin.
• The ligand activity of AGE-proteins to scavenger receptors is dependent on their rate of modification by AGEs.
• [New developments in neuromuscular blocking agents]